Lilly Back In The BACE Space Following Deal With AstraZeneca
This article was originally published in The Pink Sheet Daily
Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.
You may also be interested in...
All clear from monitoring board means firms will roll into the Phase III portion of the AMARANTH trial.
Lilly's comprehensive R&D initiative to lead in Alzheimer’s disease includes seven drugs in or nearing the clinic, with an eye on combinations. But until data from a third Phase III trial testing solanezumab read out in late 2016/early 2017, investors remain skeptical.
The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.